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Abstract 
Background: Children and adolescents with ADHD treated with central stimulants (CS) often have growth deficits, 
but the implications of such treatment for final height and stature remain unclear.
Methods: Weight and height were assessed multiple times in 410 children and adolescents during long-term treat-
ment with CS, which lasted between 0.9 and 16.1 years. Weight and height measures were converted to z-scores 
based on age- and sex-adjusted population tables.
Results: CS treatment was associated with (1) a relative reduction in body weight and a temporary halt in growth, (2) 
a weight and height lag after 72 months compared with relative baseline values. No relation to early start of medica-
tion (<6 years), gender, comorbid ODD/CD or emotional disorders was observed.
Conclusions: Treatment with central stimulants for ADHD impacts growth in children and adolescents, and growth 
should be continuously monitored in patients on chronic treatment with these medications.
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Background
The use of central stimulants (CS) for the treatment of 
ADHD has increased markedly over the past decades [1–
4] as has the number of patients remaining in treatment 
throughout puberty and into adulthood [5, 6]. This devel-
opment accentuates concern over the long-term side 
effects of CS treatment in general. The anorexic effect of 
CS [7–12] and the ensuing initial weight loss [13] is of 
particular concern for clinicians and parents caring for 
their children. The long-term impact of CS on growth 
parameters has therefore attracted much attention both 
among researchers and general public.
Studies of growth retardation in children with ADHD 
treated with CS in clinical and epidemiological studies 
report equivocal results. Some studies report growth 
retardation with catch-up of growth during drug-holidays 
or after ceasing treatment [14–17]; another study reports 
initial growth retardation with catch-up during CS treat-
ment [18]; and yet another study found initial growth 
retardation with attenuation of the decreased growth 
velocity over time [19]. Of greater concern is, however, 
reports of growth retardation during CS treatment with-
out later catch-up [20–23]. Finally, growth retardation 
in children with ADHD has also been reported to be 
independent of CS treatment, which has inspired the so-
called maturation lag hypothesis [24].
It has been proposed that the growth retardation 
effect of CS treatment is dose-dependent [20, 23, 25–
28] and may be limited to a certain subset of ADHD 
children [29, 30]. Conversely, other studies found no 
evidence to support such growth retardation or have 
questioned the clinical relevance hereof based on find-
ings of normal growth parameters in adults who were 
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treated with CS during childhood [17, 25, 27, 31–34]. A 
meta-analysis of 20 longitudinal studies concluded that 
height and weight were reduced compared to expected 
measures, but also that this effect attenuated over time 
[13].
Consensus holds that CS treatment is associated with 
initial growth retardation, but the implications of CS 
treatment for final height and stature remain unclear [6, 
13, 19, 28, 30], among others because of methodological 
limitations in the above-mentioned studies pertaining to 
issues like different dose regimes, short follow-up and 
compliance problems. A further lack in the extant lit-
erature on this issue is the absence of studies of patients 
in continuous CS treatment from childhood through 
puberty into adulthood.
The dual aims of this study are, first, to determine the 
long-term effect of CS medication on linear growth and 
body weight in patients with ADHD; and, second, we 
aim to identify subgroups susceptible to increased risk of 
growth retardation.
In the present study of 410 patients treated with CS for 
an average of 6 years (range 0.9–16.1 years), we formu-
lated five hypotheses: (1) Patients would experience an 
initial reduction in weight and halt in height; (2) Patients 
would catch up on growth parameters after 2–3  years 
of treatment; (3) There would be no gender differences 
as to hypotheses 1 and 2; (4) The following subgroups 
would be particularly susceptible to growth retarda-
tion: patients starting at a low age, patients with low 
weight prior to treatment, patients with autism or men-
tal retardation, and patients with initial weight loss; (5)
The growth retardation effect of CS treatment would be 
dose-dependent.
Methods
The characteristics of the population, details regarding 
the procedures at the ADHD clinic, and the results of the 
annual growth measurements can be seen in Tables 1 and 
2; the details have previously been published [35].
Study design
The present study is a naturalistic observational study 
[36] of 410 participants with a diagnosis of ADHD or 
ADD treated with CS. Data on these patients were gath-
ered at multiple, consecutive visits at the ADHD clinic at 
Aarhus University Hospital, Centre for Child and Adoles-
cent Psychiatry, Denmark.
In the present study, it was not possible to differenti-
ate between different types of CS with regards to sub-
stance (methylphenidate or dextroamphetamine) or with 
regards to short- vs. long-acting CS because patients 
changed medications several times in the course of the 
study.
ADHD clinic procedure
Since 1998, the clinic has monitored patients aged 7–21 
diagnosed with ADHD or ADD treated with CS. All 
patients attend the clinic at least annually (patients below 
the age of 18 are always accompanied by a primary car-
egiver). Two members of the medical staff are present at 
all visits. A consultant in child and adolescent psychia-
try and a specialised nurse are always present in visits 
involving complex cases with severe comorbidity and/or 
medication besides CS; cases who present many adverse 
effects or side effects of medication; and cases with 
severe behavioural, educational or malfunction prob-
lems. Visits involving less complex cases were staffed by 
two specialised nurses who could consult the psychiatrist 
if any questions arouse. These cases were then reviewed 
by the child and adolescent psychiatrist at weekly clinical 
conferences.
Assessment of main diagnosis at initial assessment
The patients were primarily diagnosed at a cross-disci-
plinary conference after having been assessed through 
a review encompassing their full medical and psychi-
atric history; observation at school and leisure activi-
ties; physiological examination and clinical assessment 
including neurological examination and motor function 
tests; psychological examination (at least WISC); and a 
report form (most often ADHD-RS) completed by par-
ents, school and leisure time teachers describing the 
patients’ ADHD symptoms and symptom severity. For 
patients diagnosed in their teens, observations and motor 
function tests were often replaced by an interview of the 
patient.
Assessment of comorbidity
Depending on age at baseline, all the patients were 
assessed for psychiatric comorbidity by using Kiddie-
SADS, DAWBA or another structural clinical interview. 
The choice of diagnostic tool and the different tools used 
in the study reflect the development of diagnostic instru-
ments during the study period. Patients included more 
than 10 years ago were more likely to have been assessed 
by a local structured clinical interview on the basis of 
diagnostic criteria for child and adolescent psychiatric 
disorders, whereas children included during the past 
7–8 years were more likely to have been assessed by Kid-
die-SADS or DAWBA. A comorbid diagnosis was given 
either after the primary assessment concomitantly with 
the main diagnosis or later after a new cross-disciplinary 
clinical assessment had been performed in which an MD 
participated. The latter assessment was combined with 
semi-structured interviews or report forms and a psy-
chological examination when necessary. In cases where 
the clinical assessment raised suspicion of a diagnosis of 
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pervasive developmental disorder, an ADOS and/or ADI 
was performed [37].
Assessment of growth measures (anthropometric 
assessment)
Height was measured in cm without shoes from the 
sole of the foot (the floor) to the vertex of the skull, and 
weight was assessed in kilos with the subject wearing 
indoor clothing without shoes.
We used the most recent Scandinavian growth tables 
[38, 39] to convert weight and height measures into age- 
and sex-adjusted z-scores, i.e. the difference between the 
observed value and the excepted value divided by the 
standard deviation found in the growth tables for the 
given age and sex.
Our calculations of z-scores are based on Swedish pop-
ulation norms. This approach is in line with recent Dan-
ish paediatric recommendations which argue that the 
Danish population is comparable to the Swedish regard-
ing growth data [38, 39]. The Swedish growth curves 
from 2002 are based on growth data from a retrospec-
tive longitudinal study of 3650 full-term healthy children 
born between 1973 and 1975 who were all in the 10th 
grade at school in the town of Gothenburg, Sweden. The 
children’s final height was measured at the time of the 
study, and previous height measures were obtained retro-
spectively by examining the children’s health records. The 
cohort was socioeconomically representative for Swedish 
children. Children born before the 37th week and chil-
dren with a chronic disease were excluded. The data are 
representative for Danish children according to the most 
recent weight and height curves available.
Database
In collaboration with two specialists in child and adoles-
cent psychiatry and a statistician, a database was com-
piled consisting of (1) individual factors: date of birth, 
gender, date of medication start, comorbidity and co-
medication; (2) changes in CS: date of any change, type 
of medication (Ritalin®, Ritalin Uno®, Concerta®, dexa-
mphetamine and Strattera®) and dosage (total daily dose 
and number of doses) and the reason for change; (3) vis-
its at the clinic: date, weight, height, pulse, blood pres-
sure, effect and adverse effects of medication, ADHD-RS 
Table 1 Demographic data
Male Female All
Gender 368 42 410
90 % 10 % 100 %
No Yes
Comorbidity 94 316
23 % 77 %
Autism 373 37
91 % 9 %
IQ below 90 369 41
90 % 10 %
Tics/tourette 389 21
95 % 5 %
CD/ODD 346 64
84 % 16 %
Emotional disorder 390 20
95 % 5 %
Learning disorder 185 225
45 % 55 %
Disorder of social functioning 380 30
93 % 7 %
Substance abuse 406 4
99 % 1 %
Miscellaneous 390 20
95 % 5 %
Age at start Mean Sd
9.2 2.4
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scores, SDQ scores, diagnosis and C-GAS scores; (4) all 
height and weight measurements registered since start of 
medication; (5) treatment status at the end of the survey 
or the end of the clinical visits.
Statistics/data analysis
In order to describe the possible change over time in the 
z-score for weight and height, we divided the time into five 
periods: the year before treatment start (baseline period) 
(−12 to −1 month), the first year after start (0–11 months), 
year 2–14 (12–47 months), year 5–6 (48–71 months), and 
more than 6 years after start (72+ months).
In order to describe the associations between average 
dose per kg and weight and height z-scores, we calculated 
the difference in daily weight and height scores between 
any two visits. For each date we set the dose to be the 
true dose, i.e. the latest prescribed dose, while the weight 
and z-scores were found by interpolation of the latest and 
the next measured values. From this, we could calculate 
the dose per kg for each day while taking into account the 
variation in each child’s dose and weight during the study 
period. Based on these expanded data, we calculated the 
average dose per kg, height and weight z-scores for each 
subject for each time interval.
The analyses of weight and height were based on 
the observed measurements and included data for all 
subjects who were measured at least once since 1 year 
before the start of treatment. The z-scores were ana-
lysed by repeated measurements models with random 
subject levels, and the correlation between two obser-
vations within subject decreasing with the time span 
between the measurements (Gaussian autocorrelation). 
This model specification implies that we can analyse 
data for all subjects even though some subjects only 
contributed with one or a few observations. First, we 
analysed the general development over the five time 
intervals. Second, we analysed whether the develop-
ment in growth parameters after start of CS treatment 
was influenced by age at treatment start, sex, autism, 
IQ or emotional disorder.
We tested the following three models: (1) parallel 
curves, (2) parallel curves after treatment start: and if 
the first two models could be accepted (3) no differences 
between groups.
Data management and statistical analyses were made in 
Stata 12.0 and SAS 9.2 [40, 41]; estimates are presented 
with 95 % confidence intervals (CIs); and p values below 
0.05 are considered statistically significant.
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8 27 7 8 30 7
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11+ 16 4 11+ 6 1
All periods 2209 404 99 (1; 24) 2056 403 98 (1; 15)
Period (month)
−12 to −1 
(before start)
322 293 71 (1; 4) 305 290 71 (1; 3)
0–11 328 212 52 (1; 9) 241 184 45 (1; 4)
12–47 863 356 87 (1; 11) 835 348 85 (1; 12)
48–71 393 228 56 (1; 12) 379 227 55 (1; 4)
72+ 303 135 33 (1; 7) 296 134 33 (1; s6)
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Results
Demographics
In total, 417 participants were identified representing 
the entire population of patients with ADHD assessed at 
the clinic during the study period. A total of 410 medical 
charts were reviewed. Seven charts were unavailable.
A total of 368 of the probands were male (90  %), 136 
(77  %) had one or more comorbidities: 37 autism, 21 
Tourette’s syndrome (TS) or tics, 64 conduct disorder or 
ODD, 20 emotional disorders, 225 learning disorders and 
4 substance abuse (Table 1). In 41 subjects, the IQ total 
score was below 90. Medication started in 74 (18  %) at 
the age of 3–6 years, in 204 (50 %) at 7–9 years, in 100 
(24 %) at 10–12 years, and in 32 (8 %) at 13 years or older. 
The mean age at medication start was 9.2  years (range 
3.3–17.6). The mean observation time was 6.0  years 
(range 0.9–16.1).
The number of measurements of weight and height is 
seen in Table 2.
Growth measures over time
The average z-scores for weight and height at baseline 
and at the different time intervals are illustrated in Fig. 1. 
At baseline, z-scores were significantly above the nor-
mative data for weight [M =  0.59, 95  % CI (0.43–0.74), 
p < 0.0001] and height (M = 0.21, p = 0.001), which indi-
cates a larger than expected relative weight and height.
We observed a significant reduction in z-score from 
baseline to any time interval investigated (p  <  0.0001); 
the largest decrease occurred in the interval from 
baseline to 12–47  months [M  =  −0.55 CI (−0.63; 
−0.48)], see Fig. 1. From 0–11 to 12–47 months and to 
48–71  months, a significant difference in z-scores was 
observed [M  =  −0.15; CI (−0.21; −0.09); p  <  0.0001] 
and [M  =  −0.09 (−0.18; 0.00); p  =  0.04], respectively. 
From 12–47 to 48–71 months, z-scores plateaued [0.06; 
(−0.01; 0.13); p = 0.11]; but from 12–47 to 72+ months, 
z-score increased [M = 0.15; (0.04; 0.26) p = 0.01]. The 
latter data include a similar z-score from 48–71 months 
to 72+ months [M = 0.09; (0.00; 0.18) p = 0.06].
Height z-scores decreased from baseline to any time 
interval investigated (p < 0.003 to p < −0.001). The total 
absolute reduction was 0.32, (Fig. 1). From 0–11 months 
to the following time intervals, a significant decrease was 
also found (p < 0.0001); the total absolute difference was 
0.24.
Z-scores did not exhibit a time-dependent rebound 
effect in the latter time periods.
From 12–47  months and onwards, the decrease in 
z-score was constant from time point to time point: 
12–47  months vs. 48–71  months (−0.04; p  =  0.15); 
12–47  months vs. 72+  months (−0.07: p  =  0.05); 
48–71 months vs. 72+ months (−0.03; p =  0.24); these 
decreases did not reach clinical significance and they 
indicate a plateauing of the z-score.
Moderators of growth
Gender
Means of z-scores were identical in the two groups of 
boys and girls (weight p  =  0.18, and height p  =  0.59) 
(Fig. 2). Gender was not associated with the course of the 
curves for z-weight throughout the entire time period 
(p  =  0.71) nor from 0–11  months onwards (p  =  0.96). 
Neither was this the case for z-height (p =  0.42 for the 
entire treatment time and p  =  0.41 from 0–11  months 
onwards).
In order to analyse whether a decrease in weight within 
the first year of CS treatment was a predictor for a per-
manent weight loss, we identified a group having a sig-
nificant decrease in weight z-score during the first year 
of treatment (group 1, N = 137) and compared this group 
with subjects without such a decrease (group 2, N = 23), 
Fig. 2.
At baseline, z-scores for weight were significantly above 
the normative data for both groups [M = 0.41; CI (0.13; 
0.69); p =  0.0043 for group 1 and M =  0.69; CI (0.006; 
Fig. 1 Weight and height z-scores at baseline and at 0–11 months, 
12–47 months, 48–71 months and 72+ months after treatment start 
for the entire population. The p values for statistically significant 
differences between time groups are marked. The bars indicate 95 % 
confidence intervals
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1.364) p =  0.049 for group 2]. Z-scores for weight over 
time for the 2 groups differed significantly over the entire 
treatment period (p  <  0.0001), but from 0–11  months 
onwards the curves were similar (p = 0.27).
Altogether, we saw a decrease in weight from base-
line of 0.30; this reduction ended at the level of z-score, 
i.e. within the normative range (M = 0.39, p = 0.31). In 
group 1, the z-score for weight continued to decrease, 
but to a lesser degree than the overall z-score. This con-
tinued until the 12–47  month period (M  =  −0.18), 
resulting in a total difference of 0.69 from baseline. From 
then on, weight z-scores attenuated slightly and reached 
a z-score level for weight within the normative range 
(M  =  −0.1; p  =  0.53). For group 1, the lowest z-score 
was significantly below the normative range (M = −0.28; 
p = 0.0498), whereas the lowest z-score for group 2 was 
within the normative range (M = 0.39; p = 0.31).
The two groups did not differ regarding z-score for 
height (p =  0.22). At baseline, both groups had heights 
comparable to normative data (group 1 with a height 
z-score  =  M  =  0; p  =  0.99, group 2 with a height 
z-score = M = 0.24; p = 0.38).
The two groups did not differ significantly over the 
entire period (p = 0.38) or from the 0–11-month period 
and onwards (p  =  0.84). Noteworthy is, though, that 
from the 12–47-month period and onwards, group 1 
had z-scores for height below normative data. Group 2 
z-scores remained comparable to those of the normative 
Fig. 2 Weight and height z scores at baseline and in 0–11 months, 12–47 months, 48–71 months and 72+ months after treatment start according 
to gender, age at treatment start and change in weight z score within the first year of treatment. The bars indicate 95 % confidence intervals. p(1): 
p value for test for the entire course of curves among groups (i.e. are the curves parallel?). p(2): p value for test for the course of the curves after 
0–11 months among groups (i.e. are the courses of the curves the same after 0–11 months?). p(3): p value for test for no group effect given the 
curves are parallel. If p(1) or p(2) reaches significance p(3) is omitted. The bars indicate 95 % confidence intervals
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data over the entire observation period despite the fact 
that they experienced a decline.
Analysis of CS doses revealed that subjects with a 
weight z-score decrease in the first treatment year 
received significantly higher doses than the rest of the 
study population, not only in the first treatment year, but 
also in the following time intervals.
Age at start of treatment with medication
The possible impact the age at start of medication may 
have on z-scores is shown in Fig. 2. We have shown the 
z-scores over time for the following age groups: up to 
5 years, 6–9 years, 10–11 years and 12+ years. We found 
that weight z-scores were significantly different over the 
entire period, but similar after the 0–11-month period 
and onwards. The size of the change in z-score during 
the first year of treatment was not related to age. Thus, 
the largest negative changes in z-scores were found in 
the 6–9-year-old and 10–11-year-old starters. The up-
to-5-year-old starters and the 12+ year–old starters thus 
proved to have a relatively smaller decline in z-score dur-
ing the first treatment year.
Height z-scores were similar over the entire period 
(M = 0.37) and from 0–11 months onwards (p = 0.36).
Subjects starting medication below the age of 6 gen-
erally tended to be taller than those starting medication 
later—this was not statistically significant, though. We 
found that patients starting medication below the age of 
6 showed a tendency towards higher dosages throughout 
the entire treatment period. The difference in CS doses 
became significant in the 12–47-month period (M = 0.80 
vs. M = 0.96, p = 0.007), in he 48–71-month period (0.76 
vs. 1.00  mg/kg, p  <  0.001) and in the 72+  time period 
(0.70 vs. 1.05 mg/kg, p < 0.0004).
Z‑score prior to treatment
Figure  3 illustrates z-score for weight and height in the 
year before treatment in relation to z-scores in the first 
treatment year and 4–6  years after treatment was ini-
tiation. The figure does not indicate differences in the 
susceptibility to changes in z-scores in accordance with 
lower or higher z-scores at baseline.
Dose
For weight, there was a dosage effect on the magnitude of 
change in z-scores—the larger the dose, the greater fall 
in z-score in all time periods. Furthermore, the change in 
z-score for the ≥1.5 mg/kg group continued to increase 
also in the 72+ month period; at this time reflecting an 
attenuation in the two other dosage groups.
For height there was no clear dosage effect in the 
0–11 month period. For the rest of the time periods, the 
dosage effect was clear: the higher the dose, the larger the 
fall in z-score from baseline. The 48–71-month periods 
stood out as exceptions with a fall in z-scores for the 0.5–
1.4  mg/kg and the ≥1.5  mg/kg groups of similar mag-
nitude. In the 0–0.4 mg/kg group, an attenuation of the 
change in z-score was observed at 72+ months at which 
time the other two dosage groups revealed a continued 
fall from baseline.
Table  3 illustrates the change in weight and height 
z-score from baseline for the different time periods in 
relation to the dosage (mg/kg) given in the time period 
before, i.e. change in z-scores in the 12–47-month period 
was related to dosage in the 0–11-month period.
The change since baseline was negatively associated 
with the dose in the previous period both for weight and 
height. Thus, the mean z-score for weight decreased by 
0.52 (95 % CI 0.33; 0.70) per mg/kg dose, while the mean 
z-score for height decreased by 0.33 (95 % CI 0.19; 0.47) 
per mg/kg compared with the previous period.
Comorbid autism
At baseline, subjects with and without autism both had 
weight z-scores significantly above the normative data 
(M = 0.82; p = 0.002; 0.57; p < 0.001, respectively) Fig. 4.
Subjects with autism demonstrated significantly differ-
ent changes in their z-scores for weight over the entire 
time period (p = 0.01) and from 0–11 months onwards 
(p  =  0.03) compared with non-autistic subjects. They 
had a steeper decline in weight z-score from baseline to 
0-11 months (M = 0.66 vs. M = 0.38), a smaller decrease 
from 0–11 to 12–47  months (M  =  0.01 vs. M  =  0.17) 
and a greater increase in z-score from 12–47  months 
Fig. 3 Weight and height z-scores at baseline plotted against weight 
and height z-scores at 0–11 months and 48–71 months respectively
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and onwards compared with the remaining subjects. In 
the 72+  time group, the autistic subjects again reached 
a z-score significantly greater above the normative data 
(M = 0.64; p = 0.02), whereas the z-score of non-autistic 
subjects was insignificant compared with the normative 
data (M = 0.12; p = 0.18) despite their baseline z-scores.
Height z-scores were similar in autistic and non-
autistic subjects (p =  0.36). Having an autism diagnosis 
did not affect the courses of the curves for z-height over 
the entire time period (p =  0.48) or from 0–11 months 
onwards (p = 0.52).
IQ below 90
No effect of low IQ was seen in regards to z-scores 
for weight over the entire time period (p  =  0.23) or 
from 0–11  months onwards (p  =  0.14), although there 
was a trend towards a continued decrease beyond 
12–47 months for low IQ subjects.
Subjects with low IQ generally had a lower height than 
the other children (M = −0.47; p =  0.01). At baseline, 
z-scores for height were above expected values for sub-
jects with a normal IQ (M =  0.25; p  <  0.001), whereas 
subjects with low IQ had z-scores comparable to norma-
tive data (M = −0.14; p =  0.49) There was no effect of 
low IQ on z-scores for height over the entire time period 
(p  =  0.83) or from 0–11  months onwards (p  =  0.95), 
but subjects with low IQ had reached a height z-score 
lower than normative data (M  =  −0.6; p  =  0.0045) at 
72+  months, whereas normal IQ subjects had height 
scores comparable to the normative data (M  =  −0.1; 
p = 0.39).
Dose analysis revealed that patients with low IQ had 
similar doses as the rest of the study population in the 
0–11-month and the 12–47-month periods, but sig-
nificantly higher dosages in the 48–71-month period 
(M  =  0.76 vs. 0.99  mg/kg for normal and low IQ sub-
jects respectively, p = 0.002) and the 72+ month period 
(M = 0.72 vs. 1.17 for normal and low IQ subjects respec-
tively, p = 0.001).
Emotional and behavioural disorder
Subjects with an emotional disorder (including emo-
tional disorders in childhood and depression according 
to the ICD-10 classification did not differ from others 
with regards to z-scores for weight (p = 0.94) or height 
(p  =  0.54). We observed no effect of emotional disor-
der on z-scores for weight or height over the entire time 
period (p  =  0.85 and p  =  0.74, respectively) or from 
0–11  months onwards (p =  0.72 and p =  0.60, respec-
tively). Subjects with ODD or CD did not differ from 
others with regards to z-scores over time for weight 
(p = 0.68) or for height (p = 0.69), and the general level 
Table 3 Weight and height z-scores according to month since start of treatment and average CS dose in period
Average dose in previous period Period (months from start)
0–11 12–47 48–71 72+
Weight z-score change since baseline
 0–0.4 mg/kg
  Number of persons 332 52 31 21
  Average (SD) −0.24 (0.32) −0.26 (0.70) −0.15 (1.04) −0.32 (0.90)
 0.5–1.4 mg/kg
  Number of persons 271 165 83
  Average (SD) −0.51 (0.64) −0.48 (0.89) −0.25 (1.00)
 1.5+ mg/kg
  Number of persons 6 4 1
  Average (SD) −0.61 (0.21) −0.93 (0.13) −1.47 (0.00)
Height z-score change since baseline
 0–0.4 mg/kg
  Number of persons 331 51 30 21
  Average (SD) −0.08 (0.20) −0.15 (0.41) −0.16 (0.71) −0.44 (0.60)
 0.5–1.4 mg/kg
  Number of persons 271 165 83
  Average (SD) −0.28 (0.44) −0.47 (0.64) −0.51 (0.75)
 1.5+ mg/kg
  Number of persons 6 47 1
  Average (SD) −0.43 (0.25) −0.89 (0.45) −0.12 (0.00)
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of z-scores did not differ either for weight (p = 0.92) or 
height (p = 0.61).
Discussion
The present study of the long-term effects of cen-
tral stimulants on growth parameters in patients with 
ADHD and ADD is unique with regards to the number 
of patients included, the length of the observation period 
and the number of regular assessments. The main find-
ings of our study are that (1) CS treatment of patients 
with ADHD led to a relative decrease of body weight and 
height, (2) the relative decrease of body weight stagnated 
after 12–47  months of CS treatment as did the halt in 
height growth; even after 72 months of CS treatment the 
patients had not returned to their baseline body weight 
and height values, and (3) doses and z-score decreases 
were negatively associated.
Subgroup analyses revealed that patients with a rela-
tive weight loss within the first 12  months of treatment 
suffered a larger and longer-lasting reduction in relative 
weight; and patients with concomitant ASD exhibited a 
faster and more profound relative weight loss.
The decrease in z-score for weight reported here is in 
line with numerous previous studies. The onset of catch-
up in weight z-score from 12–47 months occurred later 
than in many other studies, and the z-score remained 
below baseline for patients observed at 72  months or 
later. This contrasts with the findings of Biedermann 
Fig. 4 Weight and height z scores at baseline and at 0–11 months, 12–47 months, 48–71 months and 72+ months after treatment start for 
subjects ± autism subjects, ± IQ below 90 subjects and ± emotional disorder subjects. p(1): p value for test for the entire course of curves among 
groups (i.e. are the curves parallel?). p(2): p value for test for the course of the curves after 0–11 months among groups (i.e. are the courses of the 
curves the same after 0–11 months?). p(3): p value for test for no group effect given the curves are parallel. If p(1) or p(2) reaches significance p(3) 
is omitted. Weight and height z scores at baseline and at 0–11 months, 12–47 months, 48–71 months and 72+ months after treatment start for 
subjects below or at/over 6 years of age at treatment start. The bars indicate 95 % confidence intervals
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et  al. [34] who recorded no effect of CS on adult body 
weight in a 10-year prospective study. Inversely, our find-
ings confirm the conclusions of the MTA study, albeit it 
analyses the effects of CS treatment over a longer period. 
Whether the patients’ relative weight loss observed at 
72 months or more was clinically relevant may be ques-
tioned because the patients’ relative body weight was 
above the normative level at this time point. The patients 
weight and/or height were above normative levels prior 
to medication start as also observed for this patient group 
in several other studies [12, 19, 21, 25, 27, 42]; and this 
fact argues against the maturational lag hypothesis [24].
Our finding that the decline in z-height growth over 
time plateaued from 12–47  months without reaching 
baseline, but remained within the expected range for age, 
support the existing literature [17, 25, 27, 33, 34] that has 
questioned the clinical relevance of reduced growth rates 
by finding normal growth parameters in adults treated 
with stimulants in childhood. However, there may be 
subgroups for whom initial weight loss and attenuation 
of height velocity may have an impact [30].
Comparison of height and weight with normative data 
in the absence of standardised growth tables for patients 
with ADHD may cause conclusions about the effect of 
medication on the observed growth parameters to be 
overestimated if ADHD patients have differential growth 
patterns unrelated to their medication status [24].
We found no gender effect on growth parameters, 
which is in line with the literature.
Decrease in z‑score in the first year
We found that patients who suffered no weight loss dur-
ing their first year of treatment lost weight later. For 
patients with a weight loss in the first treatment year, the 
total weight loss was more severe and their lowest z-score 
was below normative data. However, only 162 persons 
were weighed both at baseline and in the first treatment 
year even though 212 subjects were weighed at baseline. 
Thus 52 patients who were weighed at baseline were not 
weighed during the first treatment year, and we therefore 
do not know whether they had a change in z-score. Assum-
ing that the patients who were not weighed were likely to 
have minor weight problems, we may argue that weight loss 
in the first year of CS treatment is a predictor for weight 
loss over a longer period of time and a greater weight loss 
in general and therefore for weight deficits over time.
The group with a significant weight loss in the first 
treatment year received a significantly higher CS dose 
than the group without weight loss in the first treatment 
year. Although no causality can be proved, this difference 
in dosage may be an explanation.
Age at start of stimulant treatment
We expected that CS treatment from an early age 
would have a larger impact on growth parameters than 
treatment start at an older age; but, in fact, we saw the 
opposite. This finding could not be explained by a more 
cautious titration of dosage among these young starters 
as they were treated with high dosages [35]. This con-
trasts with the literature documenting greater suscepti-
bility to adverse effects among preschool children [12]. 
We found no impact of differing age at start regarding 
z-score over time.
Our data revealed no association between low or high 
weight and/or height z-scores prior to treatment and dif-
fering susceptibility to weight or height deficits over time. 
This is not in line with the PATS study, which concluded 
that the greatest weight loss may be found in patients 
overweight prior to treatment [12].
Dosage
The impact on z-score correlated with dosage. The dos-
age effect on z-score was clear even after several years of 
treatment and could also be seen at low dosages. In line 
with earlier studies, growth retardation was seen at all 
dosages, but not in all subjects [20]. Thus, we conclude 
that other individual factors have an impact on z-score 
changes. An important bias here is that, overall, only few 
subjects were treated with high dosages, which decreases 
the statistical accuracy of this calculation.
Comorbid autism
Patients with autism experienced a larger decrease in 
weight z-score from baseline and until the 0–11-month 
period. The mechanisms lying at the root of the increased 
effect on weight in subjects with ASD remain to be inves-
tigated. In a previous paper [35], we found that autistic 
subjects did not differ from the other patients regard-
ing CS dosage which rules out dosing differences as an 
explanation. Their weight z-scores attenuated earlier, and 
at 72+ months their weight z-scores reached a level sig-
nificantly above normative data, and CS dosage therefore 
had almost no long-term impact on weight. Co-medi-
cation with orexigenic antipsychotics frequently used 
in this patient group [43] was not more frequent among 
autistic subjects than among non-autistic subjects which 
rules out orexigenic antipsychotics as an explanation. 
Selection bias may be an explanation if autistic subjects 
with growth retardation exited the clinic more frequently 
than autistic subjects without problems of growth 
retardation.
Despite the impact of autism on z-scores for weight, no 
impact of autism on the z-scores for height was revealed.
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IQ
Patients with an IQ below 90 had a tendency to experi-
ence a continued decline in weight z-score, although the 
decline fell short of statistical significance.
In a previous paper, we concluded that patients with 
an IQ below 90 received significantly higher average CS 
doses, had significantly larger dose increases over time 
and were being treated with high doses (>1.5  mg/kg) 
significantly longer and with low doses (<1  mg/kg) sig-
nificantly less than others. These differences in CS dosage 
may explain the differences in weight z-scores [35].
Patients with a low IQ generally had lower height 
z-scores than patients with a normal IQ, but we found 
no differences regarding the magnitude of the decrease 
in height z-score over time. Of clinical relevance, though, 
is the finding that subjects with a low IQ at 72+ months 
had a height z-score below the normative level even 
though they had a z-score corresponding to their norm 
at baseline. Inversely, normal-IQ subjects experienced a 
change from a larger than expected height z-score to a 
z-score corresponding to the expected level. This indi-
cates that CS treatment has a more serious impact on the 
height of low-IQ subjects than on the height of normal-
IQ subjects.
Emotional disorders
Biedermann proposed that major depressive disorder 
combined with ADHD influence the z-scores for weight 
for both genders, but in opposite directions with boys 
exhibiting lower z-scores and girls higher than expected 
z-scores [34]. In our study, we recorded no effect of emo-
tional disorders on z-scores; but, on the other hand, we 
did not specifically perform statistical analyses on the 
group of girls because the number of girls was low. More-
over, the proportion of subjects with emotional disorders 
was low, probably because only diagnoses present at the 
end of observation period were included. Another expla-
nation is that emotional disorders may have been over-
looked because their symptoms were considered part of 
the ADHD entity [35].
Strengths and limitations
Our study has several methodological shortcomings, 
the most important of which relate to its retrospective 
design. Patients have entered and exited the clinic at dif-
ferent stages of treatment and for varying reasons which 
creates problems of selection and information bias. The 
lack of control group is also a significant limitation in the 
present study. However, a control group is often not an 
option in clinical samples due to lack of clinical equipoise 
of stimulants.
The observation time was long for most patients but 
differed due to dropout of medication, dropout of clinic 
or, merely, treatment start just before the study period 
ended. Since we do not know whether patients with the 
longest follow-up differ from other patients with regards 
to growth parameters, the impact of this bias is unknown. 
If subjects contributing to the 72+  month period had 
lower z-scores before treatment than subjects who did 
not contribute to this period, the effect of CS treatment 
on the z-score may be overestimated. If subjects with 
growth problems cease medication earlier, the effect of 
CS on growth may be underestimated. Our previous 
paper concluded that those remaining in the clinic receive 
larger doses than those ending medication or those who 
are transferred to their GP [35]. Another issue of concern 
is the varying number of growth measurements between 
subjects and over time. Some patients were weighed more 
frequently than others, and this is a bias if those who were 
weighed more often differed from those who were not. 
Compliance problems, interruptions in treatment and 
dosage changes are likewise evident issues of concern in 
this study design, but these disparities reflect the clinical 
reality when treating ADHD patients.
No pubertal staging was stated in the medical charts, 
and heterogeneity of puberty and growth speed may 
therefore influence our results [26].
Co-medication was used at some point. Insufficient 
data regarding dosage, timing and duration of this treat-
ment excluded this parameter in our analysis. I it is well 
known that other psychopharmacological medications 
also influence appetite, caloric intake and growth param-
eters; and any administration of such medications may 
bias our conclusions.
This study also has a number of strengths and identi-
fies important issues that should be considered when 
treating real-life patients with ADHD. The strengths of 
the present study include a large population of patients, 
long-time follow-up of patients in continuous stimulant 
treatment, regular assessments, precise and systematic 
registration of stimulant dose over time, clinical sub-
groups which can be compared (comorbidity, age, gender, 
time of treatment), and patients were stimulant-naïve at 
baseline before entering study registration.
Conclusions
The present study contributes with valuable information 
relevant both to child and adolescent psychiatrists, adult 
psychiatrists and paediatricians. Our study identifies 
important issues relevant when compiling clinical recom-
mendations for CS treatment of patients with ADHD.
Our study shows that growth measurements need to be 
continuously taken into account when treating children 
and adolescents with stimulants.
A need remains for further clinical studies of the impact 
of growth retardation on final adult height and weight. 
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More specifically, further identification of susceptible 
subgroups is needed, the effect of stimulant dosage should 
be elucidated, and studies unravelling the anorexic and 
metabolic mechanisms of stimulants are warranted.
Highlights
  • We found a fall in relative weight and in height 
growth for patients in CS treatment; there was an 
attenuation in the decrease after 12–47  months of 
treatment, but baseline values had not been reached 
at 72+ months.
  • Changes in weight and height parameters were dose-
related.
  • Patients with decrease in relative weight within the 
first 12 months experienced a more profound relative 
weight loss.
  • Patients with weight loss in the first year experienced 
a more serious relative height deficit.
  • Children with comorbid autism had a steeper 
decrease in relative weight initially but regained a 
weight z-score above normative data.
  • Correlations with weight and height in the subgroup 
with low IQ was probably dose-related.
  • We did not find that early start of treatment led to a 
higher decrease in z-scores on weight or height.
  • We found no relation to weight or height regarding 
gender, comorbid ODD/CD or emotional disorders.
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